Aragen Bioscience Files Three Petitions for IPR on Cell-Line Patents


Aragen Bioscience, Inc. and Transposagen Biopharmaceuticals, Inc. have filed three petitions for IPR of Kyowa Hakko Kirin Co., Ltd.’s patents:  IPR2017-01262 on U.S. Patent 7,425,446; IPR2017-01252 on U.S. Patent 6,946,292; and IPR2017-01254 on U.S. Patent 8,067,232.  According to the petitions, the challenged claims are “directed to an isolated mammalian host cell producing antibodies that function more effectively because they do not have a particular fructose sugar on their Fc regions.” (See petitions at 1.)

These three patents are at issue in a district court litigation involving the same parties as those in the IPRs, 3-16-cv-05993, pending in the District Court for the Northern District of California.  According to the complaint, filed in October, 2016, Aragen and Transposagen offer cell lines that infringe the patents.

These petitions and selected other documents on IPRs concerning biologic products are posted on our IPR Tracker page.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:


Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.